Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 16th December 2019

2. Minutes and Summary Notes from last meeting

The minutes and summary notes of the Medicines Group Meeting held on 21st October 2019 were approved. The summary notes will be disseminated and published on the Trust intranet.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Beclometasone Dipropionate with Formoterol Fumarate Dehydrate and Glycopyrronium - 87micrograms/5micrograms/9micrograms per dose MDI Inhaler (Trimbow®)**

Requested by the Respiratory Team for maintenance treatment of adults with moderate-to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). This was added to the NWLIF in October 2019. It was noted at the meeting that both inhalers were added to the North West London Integrated Formulary in October 2019 and therefore any onward prescribing would be duly undertaken by the General Practitioners in Primary Care. It was agreed that triple inhalers should only be initiated on the advice of a Respiratory Physician.
Outcome: Approved for addition to the formulary

- **Fluticasone with Umeclidinium and Vilanterol - 92micrograms/55micrograms/22micrograms per dose MDI Ellipta® Inhaler (Trelegy®)**

Requested by the Respiratory Team for maintenance treatment of adults with moderate-to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA). This was added to the NWLIF in October 2019. It was noted at the meeting that both inhalers were added to the North West London Integrated Formulary in October 2019 and therefore any onward prescribing would be duly undertaken by the General Practitioners in Primary Care. It was agreed that triple inhalers should only be initiated on the advice of a Respiratory Physician.
Outcome: Approved for addition to the formulary

- **Meriofert® (Human Follicle Stimulating Hormone (FSH) Human Luteinising Hormone (LH)) Injection**

Requested by Assisted Conception unit. Meriofert® is a novel form of Menotropin where the source of LH activity is placental hCG derived from the urine of pregnant women rather than pituitary hCG derived from the urine of post-menopausal women (Menopur®). (Placental hCG has longer half-life than pituitary hCG.) Meriofert® will be used for the induction of ovulation in amenorrhoeic or anovulatory women who have not responded to treatment with Clomiphene Citrate. It will be offered initially to patients who pay privately for IVF treatment. Associated with a 14% cost saving when compared with Menopur®.
Outcome: Applicant was asked to review how patients will be selected on ACU to receive Meriofert®

Ex-panel

- **Zanamivir 10mg/ml Solution for Infusion (Dectova®)**

Requested by Microbiology Department for the treatment of patients with confirmed or suspected Influenza where 1st line Oseltamivir capsules are not appropriate based on local resistance profile or when a patient has unsafe swallow an enteral feeding tube is not available for NG administration. The Trust has been sourcing this product on compassionate named patient use for many years direct from the manufacturers, GSK. This is in line with Public Health England recommendations on the appropriate management of Influenza.

The standard dose is 600mg IV twice a day for 5 - 10 days. This equates to a treatment course of £835 (5 days) to £1,670 (10 days) assuming preserved renal function. The Antimicrobial Stewardship Group are

unable to predict the total financial impact to the Trust as the usage of zanamivir (Dectova®) will be influenced by the incidence of influenza infection each year and also the prominent strain of influenza. If an Oseltamivir resistant strain is prevalent (e.g. H1N1), then zanamivir (Dectova®) will become first line for all high-risk patient groups and usage will be widespread. Based on last year's usage of named-patient zanamivir, a conservative cost pressure of £6,000 is expected within this financial year.
Approved by Chair's Action for addition to the Trust Formulary on 30/10/2019.
Outcome: Noted

Removals
Nil

Other
- **Flecainide 10mg/ml injection (Unlicensed)**

Licensed product discontinued by the manufacturer. Obtaining unlicensed supply from varying suppliers
Proposal: Update Flecanide monograph to remove the brand name and add "Unlicensed"
Outcome: Proposed changes to the formulary approved

NICE Approved drug applications
- **TA599 - Sodium zirconium cyclosilicate for treating hyperkalaemia**

Approved by NICE in September 2019
Outcome: Approved for addition to the formulary

- **TA612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab**

Approved by NICE in November 2019
Outcome: Approved for addition to the formulary

Pharmacoeconomic Board requests
- **Tocilizumab for Cerebellar Encephalitis - Approved by PEB on 07/11/2019**

Outcome: Noted

- **Golimumab for Axial Spondyloarthritis - Approved by PEB on 25/11/2019**

Outcome: Noted

4.2 Trust Medicines Policy
- **Section 30: Supply of Over-labelled/Pre-packed medicines by Nurses/Midwives on Wards/Departments**

Updated to include:
- Addition of Dr Hickey's Clinic (Out-reach Hepatitis C Clinic) as a clinical area that can operate in line with this policy
- Doctors and pharmacists being permitted to supply and act as the checker of medicines supplied in line with this policy.
- Title reflecting that this policy is no longer undertaken by nurses/midwives only.

Decision: Approved

4.3 Medicines Optimisation
- **NWLIF current financial status and proposals for medicines cost savings**

Feedback from NWLIF on current financial position and proposals for medicine cost savings. A discussion was had on the potential cost savings NWLIF have proposed and how these will be taken forward.
Decision: Noted

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

6 Appraisals published in October 2019

TA604 - Idelalisib for treating refractory follicular lymphoma
Formulary status / Action
Nil - Not recommended

TA605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Neurology team.

TA606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema
Formulary status / Action
Nil action - Not applicable, CWFT not commissioned

TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Formulary status / Action
Currently included on the formulary for other indication.
Numbers likely to treat at CWH site: 0 patients per year - no cath lab at CWH
Numbers likely to treat at WMUH site: 50 patients per year

TA608 - Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (Terminated appraisal)
Formulary status / Action
Nil - Terminated appraisal

TA609 - Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (Terminated appraisal)
Advice
Formulary status / Action
Nil - Terminated appraisal

4 Appraisals published in November 2019

TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Urology team.

TA611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Formulary status / Action
Nil action - Not applicable, CWFT not commissioned

TA612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Oncology Team at WMUH site - See Section 4.1

TA613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
Formulary status / Action
Nil - Not recommended

b) NICE Highly Specialised Technologies published since last meeting
1 Highly Specialised Technologies published in October 2019

HST11- Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations
Formulary status / Action
Nil action - Not applicable, CWFT not commissioned

4.5 IVIG requests

- **IVIG Issues for October 2019 - CWH Site**

There were 9 IVIG issues in October 2019, with 2 new requests:
Decision: Approved

- **IVIG Issues for October 2019 - WMUH Site**

There were 16 IVIG issues in October, with 2 new requests:
Decision: Approved

- **IVIG Issues for November 2019 - CWH Site**

There were 9 IVIG issues in November 2019, with 2 new requests:
Decision: Approved

- **IVIG Issues for November 2019 - WMUH Site**

There were 16 IVIG issues in November, with 4 new requests:
Decision: Approved

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q2 2019/20**

Quarterly Controlled Drug Summary report for Q1 2019/20
Decision: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q2 2019/20**

Quarterly CD Accountable Officer report for Q2 2019/20
Decision: Noted

- **Trust Non-Medical Prescribing Register - October 2019**

Trust Non-Medical Prescribing Register for October 2019
Decision: Noted

- **Trust Patient Group Direction Tracker - November 2019**

Summary since last noting at TMG in March 2019:
  - Update PGDs (Reviewed and updated): 7 x GUM; 1 OH; 6 Maternity; 3 x Radiology; 1 x Oncology
  - New PGDs: 1 x I&A; 1 x OH; 3 x Medicine; 6 x Surgery; 15 x CBNRE
  - Suspended PGDs: 1 (Entonox for Endoscopy as expired)

Decision: Noted

- **Medication Shortages Report - November 2019**

Medication shortages Report for November 2019
Decision: Noted

- **MHRA Drug Safety Update - October 2019**

MHRA update for October 2019
Decision: Noted

- **MHRA Drug Safety Update - November 2019**

MHRA update for November 2019
Decision: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group - October 2019**

Minutes from Medication safety Group meeting - October 2019
Decision: Noted

- **HIV/GUM Directorate - Medicines Sub-Group Meeting - September 2019**

Minutes from HIV/GUM Directorate - Medicines Sub-Group meeting - September 2019
Decision: Noted

- **Antibiotic Steering Group - October 2019**

Minutes from Antimicrobial Steering Group - October 2019
Decision: Noted

4.8 Additional papers to go to Trust Patient Safety Group

- Quarterly Controlled Drug Summary Report - Q2 2019/20
- Quarterly Controlled Drugs Accountable Officer Report - Q2 2019/2019

5. Any other business

Nil

6. Date of next meeting

Date: TBC
Time: 8am-9am
Location: Main Boardroom (CWH) and meeting room A (WMUH)
Closing date: TBC